Leviticus Partners holds 235,000 Harvard Bioscience common shares, representing a 5.2% stake. The position is classified as passive because the securities were acquired in the ordinary course and not to change or influence Harvard Bioscience’s control, a distinction relevant to investors assessing ownership intent.

Key Highlights

  • Leviticus Partners’ reported position represents 5.2% of Harvard Bioscience.
  • The disclosed holding covers 235,000 common shares.
  • The securities were described as acquired in the ordinary course without a control-changing purpose.

Harvard Bioscience Inc (NASDAQ: HBIO) has a 5.2% ownership position held by Leviticus Partners LP. The reported interest covers 235,000 common shares.

Passive 5.2% Ownership Position

Leviticus Partners LP used a Schedule 13G/A to report the holding. The record identifies the security as common stock and dates the position September 14, 2026. The reported position is shown as 235,000 shares with 5.2% beneficial ownership. The ownership record also lists 235,000 shares over which Leviticus Partners LP has voting power and 235,000 shares over which it has dispositive power. Harvard Bioscience’s listed address is 84 October Hill Road, Holliston, Massachusetts 01746. Adam M Hutt is named as managing member of Leviticus Partners LP, and the record is dated September 22, 2026. The certification states that the securities were acquired and held in the ordinary course of business. It also states that the position was not acquired or held to change or influence Harvard Bioscience’s control, except for activities solely connected with a nomination under Section 240.14a-11.